Add BrightSurf on Google Email

Specialists in Global Health


Ingestible sensor-enabled Truvada®, taken as pre-exposure prophylaxis against HIV infection, identifies patterns of medication taking that may lead to risk of prophylactic failure in near real-time.

A new study reveals that ingestible sensor-enabled Truvada can identify patterns of medication taking behavior that may put individuals at risk of prophylactic failure. The system captures individual adherence patterns in real-time, allowing for tailored guidance and support.

SourceSpecialists in Global Health·JournalClinical Infectious Diseases·DateMay 22, 2022

Ingestible sensor allows patients to be independent but still supported during TB treatment

A randomized controlled trial demonstrates Wirelessly Observed Therapy (WOT) superior to directly observed therapy (DOT) in boosting TB treatment adherence, with all patients cured and preferring WOT. The novel technology allows for private medication taking while preserving patient autonomy and enabling targeted treatment support.

SourceSpecialists in Global Health·JournalPLOS Medicine·DateOct 4, 2019